A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRM+/T790M+Advanced or Recurrent NSCLC Patients

被引：0

作者：

Shi, Y. ^{[1
]}

Fang, J. ^{[2
]}

Shu, Y. ^{[3
]}

Wang, D. ^{[4
]}

Yu, H. ^{[4
]}

Zhao, Y. ^{[5
]}

Zhang, L. ^{[6
]}

Zhu, B. ^{[7
]}

Li, X. ^{[8
,14
]}

Chen, G. ^{[9
]}

Shi, J. ^{[10
]}

Zheng, R. ^{[11
]}

Huang, J. ^{[12
]}

Yang, S. ^{[1
]}

Long, J. ^{[2
]}

Gao, W. ^{[3
]}

Greco, M. ^{[13
]}

Hu, G. ^{[14
]}

Li, X. ^{[8
,14
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China

[2] Beijing Canc Hosp, Beijing, Peoples R China

[3] Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China

[4] Chongqing Canc Hosp, Chongqing, Peoples R China

[5] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China

[6] Yantai Yuhuangding Hosp, Yantai, Peoples R China

[7] Army Med Univ, PLA, Affiliated Hosp 2, Chongqing, Peoples R China

[8] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China

[9] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China

[10] Shandong Linyi Tumor Hosp, Linyi, Shandong, Peoples R China

[11] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China

[12] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China

[13] Beta Pharma, Princeton, NJ USA

[14] Beta Pharma, Shanghai, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期

关键词：

EGFR-TKI; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA01.08

引用

页码：S1126 / S1127

页数：2

共 50 条

[1] A phase I study to evaluate safety and efficacy of BPI-7711 in EGFRm+/T790M+advanced or recurrent NSCLC patients
Shi, Y.
Fang, J.
Shu, Y.
Wang, D.
Yu, H.
Zhao, Y.
Zhang, L.
Zhu, B.
Li, X.
Chen, G.
Shi, J.
Zheng, R.
Huang, J.
Yang, S.
Long, J.
Gao, W.
Greco, M.
Hu, G.
Li, X.
ANNALS OF ONCOLOGY, 2019, 30
[2] A phase I study to evaluate safety, tolerability, pharmacokinetics and antineoplastic activity of BPI-7711 in patients with EGFR/T790M mutation advanced or recurrent NSCLC.
Shi, Yuankai
Fang, Jian
Shu, Yongqian
Wang, Donglin
Yu, Huiqing
Zhao, Yanqiu
Zhang, Liangming
Zhu, Bo
Li, Xingya
Chen, Gongyan
Shi, Jianhua
Zheng, Rongsheng
Huang, Jian'An
Yang, Sheng
Long, Jieran
Gao, Wen
Greco, Michael
Wang, Jing
Li, Xiao
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
Shi, Yuankai
Wu, Shiman
Wang, Ke
Cang, Shundong
Yao, Wenxiu
Fan, Yun
Wu, Lin
Huang, Meijuan
Li, Xingya
Pan, Yueyin
Yang, Zhixiong
Zhu, Bo
Chen, Gongyan
Shi, Jianhua
Sun, Meili
Fang, Jian
Wang, Lijun
Chen, Zhaohong
Liu, Chunling
Li, Jingzhang
Liu, Jiwei
Sun, Shenghua
Zhao, Yanqiu
Guo, Yanzhen
Meng, Zili
Liu, Zhefeng
Han, Zhigang
Lu, Hong
Ma, Rui
Hu, Sheng
Zhao, Guofang
Liu, Zheng
Xie, Congying
Zhong, Diansheng
Zhao, Hui
Yu, Huiqing
Zhang, Longzhen
Bi, Minghong
Yi, Shanyong
Guo, Shuliang
Yi, Tienan
Li, Wen
Lin, Yingcheng
Shu, Yongqian
Chen, Zhendong
Guo, Zhongliang
Greco, Michael
Wang, Tingting
Shen, Haijiao
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (11) : 1306 - 1317
[4] A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naive NSCLC patients with EGFR mutation
Shi, Y-K.
Zhou, J.
Zhao, Y.
Zhu, B.
Zhang, L.
Li, X.
Fang, J.
Shi, J.
Zhuang, Z.
Yang, S.
Wang, D.
Yu, H.
Zhang, L.
Zheng, R.
Greco, M.
Wang, T.
Mo, F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1000 - S1000
[5] Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, singlearm, open-label study.
Wu, Shiman
Wang, Ke
Cang, Shundong
Yao, Wenxiu
Fan, Yun
Wu, Lin
Huang, Meijuan
Li, Xingya
Pan, Yueyin
Yang, Zhixiong
Zhu, Bo
Chen, Gongyan
Shi, Jianhua
Sun, Meili
Fang, Jian
Wang, Lijun
Chen, Zhaohong
Greco, Michael
Wang, Tingting
Shi, Yuankai
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study
Shi, Yuankai
Zhao, Yanqiu
Yang, Sheng
Zhou, Jianying
Zhang, Liangming
Chen, Gongyan
Fang, Jian
Zhu, Bo
Li, Xingya
Shu, Yongqian
Shi, Jianhua
Zheng, Rongsheng
Wang, Donglin
Yu, Huiqing
Huang, Jianan
Zhuang, Zhixiang
Wu, Gang
Zhang, Longzhen
Guo, Zhongliang
Greco, Michael
Li, Xiao
Zhang, Yu
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) : 708 - 717
[7] Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
Shi, Yuankai
Zhou, Jianying
Zhao, Yanqiu
Zhu, Bo
Zhang, Liangming
Li, Xingya
Fang, Jian
Shi, Jianhua
Zhuang, Zhixiang
Yang, Sheng
Wang, Donglin
Yu, Huiqing
Zhang, Longzhen
Zheng, Rongsheng
Greco, Michael
Wang, Tingting
BMC MEDICINE, 2023, 21 (01)
[8] Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
Yuankai Shi
Jianying Zhou
Yanqiu Zhao
Bo Zhu
Liangming Zhang
Xingya Li
Jian Fang
Jianhua Shi
Zhixiang Zhuang
Sheng Yang
Donglin Wang
Huiqing Yu
Longzhen Zhang
Rongsheng Zheng
Michael Greco
Tingting Wang
BMC Medicine, 21
[9] Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies
Yang, Sheng
Wu, Shiman
Zhao, Yanqiu
Chen, Gongyan
Zhu, Bo
Li, Xingya
Wang, Ke
Shi, Jianhua
Cang, Shundong
Yao, Wenxiu
Fan, Yun
Fang, Jian
Zhang, Liangming
Zhou, Jianying
Wu, Lin
Zheng, Rongsheng
Huang, Meijuan
Pan, Yueyin
Yang, Zhixiong
Sun, Meili
Yu, Huiqing
Wang, Donglin
Huang, Jianan
Wang, Lijun
Shu, Yongqian
Chen, Zhaohong
Liu, Chunling
Li, Jingzhang
Liu, Jiwei
Sun, Shenghua
Guo, Yanzhen
Meng, Zili
Liu, Zhefeng
Han, Zhigang
Wu, Gang
Lu, Hong
Ma, Rui
Hu, Sheng
Zhao, Guofang
Zhang, Longzhen
Liu, Zheng
Xie, Congying
Zhong, Diansheng
Zhao, Hui
Bi, Minghong
Yi, Shanyong
Guo, Shuliang
Yi, Tienan
Li, Wen
Lin, Yingcheng
LUNG CANCER, 2023, 180
[10] A Phase 1, 2 Study to Evaluate the Safety and Antitumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC
Lim, S. M.
Cho, B. C.
Nagasaka, M.
Reungwetwattana, T.
Jo, A.
Seah, E.
Kim, C.
Ou, S. -H. I.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S335 - S335

← 1 2 3 4 5 →